Status of drug discovery-based marine biotechnology in Southeast Asia
Tan, L.K.; Widyantoro, C.; Hanif, N. (2025). Status of drug discovery-based marine biotechnology in Southeast Asia, in: Tan, L.K. et al. Marine natural products research in south-east Asia: Current status and perspectives. pp. 1-62. https://dx.doi.org/10.1007/978-3-032-01098-8_1
|
| Authors | | Top |
- Tan, L.K.
- Widyantoro, C.
- Hanif, N.
|
|
|
| Abstract |
Southeast Asia, a region renowned for its rich marine biodiversity, has emerged as a critical hub for marine natural products (MNPs) research. This introductory chapter provides a comprehensive overview of the current status of marine biotechnology in the region, particularly its application in drug discovery. Key Southeast Asian countries, including Indonesia, Vietnam, Thailand, Malaysia, the Philippines and Singapore, have made notable advancements in exploring marine organisms, such as sponges, tunicates, soft corals, echinoderms and algae, for bioactive compounds. These marine taxa have been shown to yield diverse metabolites with potential pharmacological uses, including antimicrobial, anticancer and anti-inflammatory properties. Despite this potential, the development of marine drug discovery programs across Southeast Asia remains uneven, with disparities in research capacity, infrastructure and international collaboration. The region faces pressing challenges, including overfishing, pollution and climate change, which threaten the very biodiversity it depends upon. Additionally, there are substantial opportunities for leveraging traditional marine medicine knowledge and transitioning toward sustainable blue economy frameworks. This chapter sets the stage for the book by summarizing the marine biotechnological landscape across Southeast Asia, identifying key biodiversity resources, ongoing initiatives, and gaps in knowledge and infrastructure that need to be addressed for future innovation and conservation. |
|
